URGN

UroGen Pharma Ltd.

Price

$44.49

return (12m)

129.66%

p/e

-22.30

p/bv

-16.45

DIVIDEND YIELD

0.00%

URGN price

UroGen Pharma

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment URGN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-2.83%

3 months

65.68%

1 year

129.66%

2 years

228.06%

5 years

148.24%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals URGN

Valuation

P/E

-22.30

Sector -4.23

Industry -4.23

P/BV

-16.45

Sector 2.11

Industry 2.11

P/Revenue (PSR)

11.54

Sector 2.05

Industry 2.05

EV/EBITDA

Sector -546.75

Industry -546.75

EV/EBIT

Sector -37.85

Industry -37.85

P/EBITDA

Sector -51.33

Industry -51.33

P/EBIT

Sector -39.56

Industry -39.56

P/Total Assets

8.62

Sector 1.25

Industry 1.25

P/Net Current Assets

-14.56

Sector -5.36

Industry -5.36

P/Working Capital

12.55

Sector -1.24

Industry -1.24

EPS

-1.95

Sector -1.92

Industry -1.92

BVPS

-2.65

Sector 1.93

Industry 1.93

Efficiency

Gross Margin

90.84%

Sector 39.10%

Industry 39.10%

EBITDA Margin

0.00%

Sector -13,872.36%

Industry -13,872.36%

EBIT Margin

0.00%

Sector -4,235,733.26%

Industry -4,235,733.26%

Operating Margin

-35.31%

Sector -36.62%

Industry -36.62%

Net Profit Margins

-51.73%

Sector -37.41%

Industry -37.41%

Asset Turnover

0.29

Sector 0.03

Industry 0.03

Profitability

ROE

73.74%

Sector -60.49%

Industry -60.49%

ROA

-38.65%

Sector -63.06%

Industry -63.06%

ROIC

0.00%

Sector -498.28%

Industry -498.28%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

3.80

Sector 2.90

Industry 2.90

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

-1.43

Sector -38,821.65

Industry -38,821.65

Gross Debt / Equity

-1.43

Sector -0.83

Industry -0.83

Equity/Assets

-0.52

Sector 0.43

Industry 0.43

Liabilities/Assets

1.52

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

31.48%

Sector -

Industry -

5Y Earnings CAGR

-2.50%

Sector -

Industry -

Fundamentals URGN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
URGN UroGen Pharma Ltd.	$44.49	127.78%	0.00%	-22.30	-16.45	73.74%	-51.73%
JNJ Johnson & Johnson	$277.82	60.73%	1.98%	30.34	7.51	24.76%	21.48%
PFE Pfizer Inc.	$28.67	22.83%	6.28%	35.72	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$260.84	27.01%	2.66%	72.02	-76.66	-106.44%	9.81%
NVO Novo Nordisk A/S	$47.05	-12.95%	4.06%	11.16	5.92	53.11%	35.32%
MRK Merck & Co. Inc.	$151.13	83.70%	2.29%	114.53	8.64	7.55%	4.76%
AZN AstraZeneca PLC	$164.27	2.46%	1.99%	23.89	4.95	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.65	49.46%	3.79%	14.60	6.06	41.55%	18.85%
ZTS Zoetis Inc.	$75.60	-49.60%	2.68%	12.14	10.20	84.02%	27.77%
AMGN Amgen Inc.	$443.34	60.06%	2.28%	26.55	19.86	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$841.88	49.91%	0.58%	18.86	2.57	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$110.11	50.14%	0.00%	29.70	85.59	288.14%	24.86%
MCK McKesson Corporation	$920.40	33.76%	0.37%	20.12	-27.60	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$557.35	38.99%	0.00%	31.27	6.80	21.76%	35.00%
CAH Cardinal Health Inc.	$247.26	67.44%	0.87%	35.62	-20.64	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$42.74	15.20%	0.00%	12.57	2.28	18.14%	18.89%
ARGX argenx SE	$1,061.23	50.23%	0.00%	3.11	3.48	112.18%	44.41%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

URGN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT UroGen Pharma

UroGen Pharma Ltd.

Average Investor10 user rating

4.0 (0 people)

United States

22 years

Founded: 2004

2017

Time since IPO - 9 years

173

Employees

UroGen Pharma Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $2.18 billion, with shareholders equity totaling $-132.40 million.

The company employs approximately 173 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, UroGen Pharma Ltd. reported $188.74 million in revenue, generating net income of $-97.63 million.

Key financial metrics include a P/E ratio of -22.30, a price-to-book (P/B) ratio of -16.45, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker URGN.

Market cap

$2.18 billion

Net worth

$-132.40 million

$-132,400,000.00

Assets

$252.59 million

$252,590,000.00

Total Shares Outstanding

50.00 million

50,000,000

Average Daily Trading Volume

$855.64 Thousand

$855,642.00

Sector

Health Care

Industry

Biotechnology

URGN

URGN revenue and profits

Financial Results URGN

DRAG THE FRAME TO SEE MORE DATA

URGN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$920.40 33,91% (12M)

P/E

20.12

0.37%

ROE

-137.16%

P/BV

-27.60

CAH - Cardinal Health

$247.26 66,32% (12M)

P/E

35.62

0.87%

ROE

-57.93%

P/BV

-20.64

JNJ - Johnson & Johnson

$277.82 60,78% (12M)

P/E

30.34

1.98%

ROE

24.76%

P/BV

7.51

ABBV - AbbVie

$260.84 27,05% (12M)

P/E

72.02

2.66%

ROE

-106.44%

P/BV

-76.66

MRK - Merck & Co.

$151.13 86,53% (12M)

P/E

114.53

2.29%

ROE

7.55%

P/BV

8.64

AZN - AstraZeneca

$164.27 2,98% (12M)

P/E

23.89

1.99%

ROE

20.74%

P/BV

4.95

PFE - Pfizer

$28.67 23,78% (12M)

P/E

35.72

6.28%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$920.40 33,91% (12 M)

P/L

20.12

0.37%

ROE

-137.16%

P/VP

-27.60

CAH - Cardinal Health

$247.26 66,32% (12 M)

P/L

35.62

0.87%

ROE

-57.93%

P/VP

-20.64

JNJ - Johnson & Johnson

$277.82 60,78% (12 M)

P/L

30.34

1.98%

ROE

24.76%

P/VP

7.51

ABBV - AbbVie

$260.84 27,05% (12 M)

P/L

72.02

2.66%

ROE

-106.44%

P/VP

-76.66

MRK - Merck & Co.

$151.13 86,53% (12 M)

P/L

114.53

2.29%

ROE

7.55%

P/VP

8.64

AZN - AstraZeneca

$164.27 2,98% (12 M)

P/L

23.89

1.99%

ROE

20.74%

P/VP

4.95

PFE - Pfizer

$28.67 23,78% (12 M)

P/L

35.72

6.28%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of UroGen Pharma (URGN) today?

A cotação de UroGen Pharma (URGN) hoje está em US$ 44.49, com uma variação de 129.66% em relação ao último ano. A cotação de UroGen Pharma (URGN) iniciou o ano negociando na casa dos US$ 23.42 e hoje está em US$ 44.49. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de UroGen Pharma (URGN) e dados de ações do Ibovespa e mercados internacionais.

Quando UroGen Pharma (URGN) paga dividendos?

UroGen Pharma (URGN) não distribuiu dividendos no último ano.

Is UroGen Pharma (URGN) a good investment?

Atualmente, UroGen Pharma (URGN) está cotada a US$ 44.49, com um P/L de -22.30, representando um desvio de -833% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 129.66 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 129.66%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy UroGen Pharma (URGN) stock?

Investir em ações de UroGen Pharma (URGN) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of UroGen Pharma (URGN) yield today?

A rentabilidade de UroGen Pharma (URGN) foi de -2.83% no último mês, 129.66% no último ano e 148.24% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de UroGen Pharma (URGN) hoje, o investimento total seria de US$ 4,448.50, com base na cotação atual de US$ 44.49.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 10,216.43
Em 5 anos: US$ 11,042.96
Em 10 anos: US$ 4,448.50

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

URGN

UroGen Pharma Ltd.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment URGN

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING URGN WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT UroGen Pharma

UroGen Pharma Ltd.

United States

22 years

2017

173

PROFIT X PRICE URGN

Financial Results URGN

URGN cash flow

Asset, Revenue and Profit Growth - URGN

URGN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions